Skin of Color pp 221-236 | Cite as

Overview of Cosmetic Concerns in Skin of Color

  • Heather Woolery-Lloyd
  • Jenna N. Kammer


Physicians are confronted with a myriad of cutaneous diseases affecting those with skin of color. Patients with skin of color, which includes individuals of African, Asian, and Hispanic descent, have unique cosmetic concerns. Such patients often require special consideration when it comes to receiving cosmetic procedures. These patients are particularly vulnerable because any kind of significant trauma, whether it is from a laser or chemical peel, can cause long-lasting or permanent pigmentary changes. For the clinician, cosmetic procedures with patients of skin of color can be challenging because of this increased risk of hyperpigmentation and scarring. Due to enhanced technology and scientific advances, the demand to seek procedures to address these patients’ cosmetic concerns has reached new heights. Patients with skin of color who request cosmetic procedures have various motivations and goals. They may want to attain even skin tone, remove unwanted hair, and/or reduce the signs of aging. This chapter will provide a systematic overview of the cosmetic concerns for those with skin of color by describing the practical approaches to treating pigmentary disorders, keloids, dermatosis papulosa nigra (DPN), unwanted hair, skin laxity, and photoaging in those with skin of color.


Skin Type Azelaic Acid Kojic Acid Tyrosinase Inhibitor Fluocinolone Acetonide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Grimes PE. Skin and hair cosmetic issues in women of color. Dermatol Clin. 2000;18(4): 659–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Penney KB, Smith CJ, Allen JC. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes. J Invest Dermatol. 1984;82:308–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Bates B. Derms react to possible FDA ban of hydroquinone: cite poor scientific reasoning, ethnic bias. Skin Allergy News. 2007;38(1):20.CrossRefGoogle Scholar
  4. 4.
    Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Vener. 2006;20(7):781–7.CrossRefGoogle Scholar
  5. 5.
    Lawrence N, Bligard CA, Reed R, et al. Exogenous ochronosis in the United States. J Am Acad Dermatol. 1988;18:1207–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Huang PY, Chu CY. Allergic contact dermatitis due to sodium metabisulfite in a bleaching cream. Contact Dermatitis. 2007;56(2):123–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Fitton A, Goa KL. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991;41:780–98.PubMedCrossRefGoogle Scholar
  8. 8.
    Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28(2):77–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Garcia A, Fulton Jr JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22(5):443–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32(1):9–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Jones K, Hughes J, Hong M, et al. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res. 2002;15(5):335–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Piao LZ, Park HR, Park YK, et al. Mushroom tyrosinase inhibition activity of some chromones. Chem Pharm Bull(Tokyo). 2002;50(3):309–11.CrossRefGoogle Scholar
  13. 13.
    Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002;27(6):513–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Babiarz-Magee L, Chen N, Seiberg M, Lin CB. The expression and activation of protease-activated receptor-2 correlate with skin color. Pigment Cell Res. 2004;17(3):241–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Paine C, Sharlow E, Liebel F. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001;116:585–95.CrossRefGoogle Scholar
  16. 16.
    Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in photoaging: a double-blind, vehicle-controlled, 12-week study. J Drugs Dermatol. 2007;6(9):917–22.PubMedGoogle Scholar
  17. 17.
    Middelkamp-Hup MA, Pathak MA, Parrado C, Goukassian D, Rius-Díaz F, Mihm MC, Fitzpatrick TB, González S. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004;51(6):910–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Woolery-Lloyd H, Martin L. A randomized double-blind placebo controlled study evaluating the effectiveness and tolerability of oral Polypodium leucotomos in patients with melasma J Am Acad of Dermatol. 2012;66(4(suppl 1)):AB21.Google Scholar
  19. 19.
    Lee WR, Shen SC, Kuo-Hsien W, Hu CH, Fang JY. Lasers and microdermabrasion enhance and control topical delivery of vitamin C. J Invest Dermatol. 2003;121(5):1118–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Rajan P, Grimes PE. Skin barrier changes induced by aluminum oxide and sodium chloride microdermabrasion. Dermatol Surg. 2002;28(5):390–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg. 2003;29: 1050–1.PubMedCrossRefGoogle Scholar
  22. 22.
    Mathangi-Ramakrishnan K, Pothan-Thomas K, Cheyyur R. Study of 1,000 patients with keloidal scars in South India. Plast Reconstr Surg. 1974;53:276–80.CrossRefGoogle Scholar
  23. 23.
    Cosman B, Wolff M. Correlation of keloid recurrence with completeness of local excision: a negative report. Plast Reconstr Surg. 1972;50:163–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg. 1991;27:164–78.PubMedCrossRefGoogle Scholar
  25. 25.
    Conway H, Gillette RW, Findley A. Differential diagnosis of keloids and hypertrophic scars by tissue culture techniques with notes on therapy of keloids by surgical excision and decadron. Plast Reconstr Surg. 1960;25:117–32.CrossRefGoogle Scholar
  26. 26.
    Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999;104:1435–58.PubMedCrossRefGoogle Scholar
  27. 27.
    Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002;47(4):S209–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Tosa M, Ghazizadeh M, Shimizu H, et al. Global gene expression analysis of keloid fibroblasts in response to electron beam irradiation reveals the involvement of interleukin-6 pathway. J Invest Dermatol. 2005;124:704–13.PubMedCrossRefGoogle Scholar
  29. 29.
    Lupo MP. Dermatosis papulosa nigra: treatment options. J Drugs Dermatol. 2007;6(1): 29–30.PubMedGoogle Scholar
  30. 30.
    Wolf Jr JE, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007;46(1):94–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol. 2007;57(1):54–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Adrian RM, Shay KP. 800 nanometer diode laser hair removal in African American patients: a clinical and histologic study. J Cutan Laser Ther. 2000;2(4):183–90.PubMedGoogle Scholar
  33. 33.
    Greppi I. Diode laser hair removal of the black patient. Lasers Surg Med. 2001;28(2):150–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Alster TS, Bryan H, Williams CM. Long-pulsed Nd:YAG laser-assisted hair removal in pigmented skin: a clinical and histological evaluation. Arch Dermatol. 2001;137(7):885–9.PubMedGoogle Scholar
  35. 35.
    Ross EV, Cooke LM, Timko AL, Overstreet KA, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. 2002;47(2):263–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Zelickson BD, Kist D, Bernstein E, et al. Histological and ultrastructural evaluation of the effects of a radiofrequency based nonablative dermal remodeling device: a pilot study. Arch Dermatol. 2004;140(2):204–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Fitzpatrick R, Geronemeus R, Goldberg D, et al. Multicenter study of noninvasive radiofrequency for periorbital tissue tightening. Lasers Surg Med. 2003;33:232–42.PubMedCrossRefGoogle Scholar
  38. 38.
    Chua SH, Ang P, Khoo LS, Goh CL. Nonablative infared skin tightening in Type IV to V Asian skin: a prospective clinical study. Dermatol Surg. 2007;33(2):146–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Kaidbey KH, Agin PP, Sayre RM, Kaidbey KH, Agin PP, Sayre RM, et al. Photoprotection by melanin – a comparison of black and Caucasian skin. J Am Acad Dermatol. 1979;1(3):249–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Woolery-Lloyd H. Skin of color. In: Baumann L, editor. Cosmetic dermatology. 2nd ed. New York: McGraw-Hill; 2009. p. 115.Google Scholar
  41. 41.
    Herzberg AJ, Dinehart SM. Chronologic aging in black skin. Am J Dermatopathol. 1989;11:319–28.PubMedCrossRefGoogle Scholar
  42. 42.
    America Society for Aesthetic plastic surgery. Cosmetic surgery national data bank statistics. Accessed 5 July 2009.
  43. 43.
    Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of Botulinum Toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg. 2009;35(3):429–36.PubMedCrossRefGoogle Scholar
  44. 44.
    Jackson BA. Cosmetic considerations and nonlaser cosmetic procedures in ethnic skin. Dermatol Clin. 2003;21:703–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Hexsel DM, Hexsel CL, Brunetto LT. Botulinum toxin. In: Grimes PE, editor. Aesthetic and cosmetic surgery for darker skin types. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 211–24.Google Scholar
  46. 46.
    Flynn TC, Carruthers JA, Carruthers JA. Botulinum A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27:703–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Yu CC, Chen PK, Chen YR. Botulinum toxin a for lower facial contouring: a prospective study. Aesthetic Plast Surg. 2007;31(5):445–51. discussion 452–453.PubMedCrossRefGoogle Scholar
  48. 48.
    Brugges CM. Soft tissue augmentation in skin of color: market growth, available fillers, and successful techniques. J Drugs Dermatol. 2007;6:51–5.Google Scholar
  49. 49.
    Matory WE. Aging in people of color. In: Matory WE, editor. Ethnic considerations in facial aesthetic surgery. Philadelphia: Lippincott-Raven; 1998. p. 151–70.Google Scholar
  50. 50.
    Odunze M, Cohn A, Few JW. Restylane and people of color. Plast Reconstr Surg. 2007;120(7):2011–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.University of Miami Cosmetic Medicine and Research InstituteMiami BeachUSA
  2. 2.Drexel University College of MedicinePhiladelphiaUSA

Personalised recommendations